Transarterial embolisation not cost effective vs sorafenib for hepatocellular carcinoma
Source: PharmacoEconomics and Outcomes News - Category: Drugs & Pharmacology Source Type: news
More News: Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Hepatocellular Carcinoma | Liver Cancer